Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Revenue (2016 - 2025)

Historic Revenue for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $159.9 million.

  • Ultragenyx Pharmaceutical's Revenue rose 1465.22% to $159.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $630.6 million, marking a year-over-year increase of 2063.2%. This contributed to the annual value of $560.2 million for FY2024, which is 2901.12% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Revenue is $159.9 million, which was up 1465.22% from $166.5 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Revenue registered a high of $166.5 million during Q2 2025, and its lowest value of $79.9 million during Q1 2022.
  • For the 5-year period, Ultragenyx Pharmaceutical's Revenue averaged around $114.5 million, with its median value being $103.3 million (2022).
  • Its Revenue has fluctuated over the past 5 years, first surged by 17374.76% in 2021, then tumbled by 1957.84% in 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Revenue (Quarter) stood at $83.4 million in 2021, then grew by 23.93% to $103.3 million in 2022, then rose by 23.27% to $127.4 million in 2023, then grew by 29.42% to $164.9 million in 2024, then decreased by 3.0% to $159.9 million in 2025.
  • Its Revenue stands at $159.9 million for Q3 2025, versus $166.5 million for Q2 2025 and $139.3 million for Q1 2025.